Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
This expansion follows the groundbreaking of a large-scale commercial drug product facility in Stein (CH), in another milestone for Lonza’s Drug Product Services (DPS) offering
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
_256_384.png)
Leuprolide Acetate Injection Depot contains 22.5 mg of leuprolide acetate for 3- month administration given as a single dose injection.
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Subscribe To Our Newsletter & Stay Updated
